Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type (Hormone Therapies, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Others), By Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Others), By End User (Hospitals & Clinics, Cancer & Radiation Therapy Centers, Academic & Research Institutions), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 16.82 Billion
CAGR (2026-2031)	7.71%
Fastest Growing Segment	Breast Cancer
Largest Market	North America
Market Size (2031)	USD 26.26 Billion

Market Overview

The Global Targeted Cancer Therapy Market is projected to grow from USD 16.82 Billion in 2025 to USD 26.26 Billion by 2031 at a 7.71% CAGR. Targeted cancer therapy represents a precise medical approach that identifies and selectively attacks cancer cells based on their distinct molecular characteristics, thereby minimizing adverse effects on healthy tissues. The global market's expansion is primarily driven by the increasing worldwide incidence of cancer, significant advancements in genomic understanding and biomarker identification, and a growing demand for personalized and highly effective treatment modalities.

Illustrating ongoing innovation, according to PhRMA's 2025 Annual Report, fourteen oncology approvals, encompassing targeted therapies, were granted in 2025. Despite this progress, a significant impediment to market expansion remains the substantial financial burden associated with developing and commercializing these complex therapies, coupled with stringent regulatory approval processes that contribute to extended timelines for market entry.

Key Market Drivers

The escalating global cancer incidence and burden represents a primary impetus for the targeted cancer therapy market. As diagnoses rise worldwide, demand for advanced and effective treatment options surges, driving the development and adoption of precise therapies. According to research published in The Lancet in September 2025, over 18 million new incident cases of cancer occurred globally in 2023. This increasing prevalence necessitates continuous innovation in oncology, with targeted therapies offering potential for improved patient outcomes by addressing molecular drivers of cancer. The growing patient population requiring treatment underscores the ongoing need for therapeutic advancements in this field.

Significant advancements in precision medicine and genomic research further propel the market. Deeper understanding of cancer's molecular underpinnings enables identification of specific biomarkers and genetic mutations, fostering highly individualized treatments. This progress is backed by substantial industry investment. For instance, according to Novartis, in April 2025, the company announced a planned $23 billion investment over five years in US-based infrastructure, including an expansion of its research and development footprint focused on oncology. Such investments facilitate the discovery and clinical translation of novel targeted agents. These innovations contribute to the overall growth of the oncology pharmaceutical landscape, with GSK's oncology portfolio sales for fiscal year 2025 growing by 43% to just under £2 billion, according to Pharmaceutical Technology in February 2026.

Download Free Sample Report

Key Market Challenges

The substantial financial burden associated with developing and commercializing targeted cancer therapies represents a significant impediment to the growth of the global market. The intricate research and development required for identifying precise molecular targets, synthesizing novel compounds, and conducting extensive preclinical and clinical trials demand considerable capital investment. This high cost of innovation directly influences the pricing strategies of these therapies, potentially limiting their accessibility and adoption across diverse healthcare systems.

Coupled with the financial demands, stringent regulatory approval processes contribute to extended timelines for market entry, further exacerbating the challenge. The rigorous requirements for demonstrating safety and efficacy in highly specific patient populations often necessitate prolonged clinical development phases and extensive data submission. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the average time from clinical trial start to patient enrolment close increased by 26% from 2019 to 2023. These protracted development cycles not only inflate R&D expenditures but also delay return on investment for pharmaceutical companies, thereby constraining further investment into new targeted therapy research and development.

Key Market Trends

The integration of artificial intelligence is fundamentally reshaping the targeted cancer therapy landscape by accelerating drug discovery and diagnostic development. AI algorithms analyze vast genomic and proteomic datasets, identifying novel drug targets and predicting patient responses with increased precision, which streamlines early-stage research. This integration helps minimize the time and cost associated with bringing new therapies to market by optimizing compound design. According to Forbes, in March 2026, Roche launched a large-scale AI factory with an estimated investment of $65 million to $87 million in Nvidia Blackwell GPUs, dedicated to accelerating the development of new drugs and diagnostics. This investment highlights the industry's commitment to leveraging AI for enhanced efficiency across the therapeutic value chain.

A significant trend also involves the emergence of next-generation targeted therapies, moving beyond traditional small molecules and antibodies to incorporate advanced modalities. These include sophisticated cell therapies, gene therapies, and novel conjugate platforms that offer enhanced specificity and efficacy against previously intractable cancers. Such innovations aim to overcome mechanisms of treatment resistance and address unmet needs in patient populations. As an illustration, according to BioPharma Dive, in April 2026, Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, with an upfront payment of $3.25 billion, for its iGPS technology which facilitates in vivo CAR-T cell engineering. This acquisition signals a strategic shift towards transformative therapeutic approaches in oncology.

Segmental Insights

The breast cancer segment is a key driver in the global targeted cancer therapy market, demonstrating rapid expansion due to significant advancements in precision medicine. This growth is primarily fueled by the increasing global incidence of breast cancer, alongside continuous innovation leading to the frequent launch of novel targeted therapies. Regulatory bodies, such as the U.S. Food and Drug Administration, have played a crucial role through consistent approvals of new agents, including antibody-drug conjugates and selective estrogen receptor degraders, which offer enhanced efficacy and more tailored treatment approaches. Furthermore, a rising emphasis on early detection and biomarker-driven strategies ensures that a broader patient population benefits from these advanced, personalized interventions, minimizing recurrence risk and improving outcomes.

Regional Insights

North America stands as the leading region in the global targeted cancer therapy market, primarily due to a substantial cancer incidence and a highly conducive regulatory environment. The region boasts a robust healthcare infrastructure that supports extensive research and development initiatives, alongside significant investment in oncology. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), play a crucial role by facilitating timely approvals for innovative targeted therapies and personalized medicine approaches. This framework, coupled with the strong presence of key biotechnology and pharmaceutical companies, drives innovation and ensures rapid market penetration for advanced cancer treatments.

Recent Developments

• In April 2026, Telix Pharmaceuticals entered a collaboration agreement with Regeneron to develop new targeted cancer treatments. This partnership combined Telix's capabilities in radiopharmaceutical development, manufacturing, and global supply with Regeneron's expertise in antibody discovery and oncology research. The companies intend to integrate biologics, such as bispecific antibodies, with targeted radiation to create therapies that precisely target cancer cells while minimizing impact on healthy tissue. The agreement included an upfront payment of US$40 million to Telix for four initial programs.
• In January 2026, Eli Lilly and Company announced that its investigational targeted therapy, sofetabart mipitecan (LY4170156), received Breakthrough Therapy designation from the U.S. FDA. This designation was granted for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, specifically those who had received prior bevacizumab and mirvetuximab soravtansine. Sofetabart mipitecan is a novel folate receptor alpha (FRα) antibody-drug conjugate, and this regulatory milestone facilitates its expedited development as a targeted cancer therapy.
• In June 2025, Nuvation Bio received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a new oral treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This next-generation oral ROS1 tyrosine kinase inhibitor (TKI) demonstrated high and durable response rates, alongside intracranial activity, in pivotal clinical trials. The approval followed a Priority Review, establishing IBTROZI as a new targeted therapeutic option for patients in need of advanced ROS1+ NSCLC treatment, and contributing to the global targeted cancer therapy market.
• In January 2025, Molecular Partners and Orano Med expanded their strategic collaboration to develop additional targeted alpha radio-therapies for cancer. The new agreement encompassed the development of six extra targeted alpha therapeutic candidates, increasing their combined portfolio to ten programs. This partnership leverages Orano Med's expertise in developing lead-212 (212Pb) based targeted alpha-particle therapies and Molecular Partners' Radio-DARPins as a vector for radiopharmaceuticals, highlighting a significant collaboration in the targeted cancer therapy landscape.

Key Market Players

• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Service Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.

By Therapy Type	By Disease Indication	By End User	By Region
Hormone Therapies Monoclonal Antibodies Signal Transduction Inhibitors Gene Expression Modulators Apoptosis Inhibitors Others	Lung Cancer Breast Cancer Colorectal Cancer Leukemia Melanoma Lymphoma Others	Hospitals & Clinics Cancer & Radiation Therapy Centers Academic & Research Institutions	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Targeted Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Targeted Cancer Therapy Market, By Therapy Type:

• Hormone Therapies
• Monoclonal Antibodies
• Signal Transduction Inhibitors
• Gene Expression Modulators
• Apoptosis Inhibitors
• Others

• Targeted Cancer Therapy Market, By Disease Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Melanoma
• Lymphoma
• Others

• Targeted Cancer Therapy Market, By End User:

• Hospitals & Clinics
• Cancer & Radiation Therapy Centers
• Academic & Research Institutions

• Targeted Cancer Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE